Physician profile
Raj Parikh
NPI 1790122794
$386,384.77
in general payments reported to CMS, 2019-2025
20 companies · $181K in 2025
The $181K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.72 · 2021: $551 · 2022: $6,585 · 2023: $55K · 2024: $143K · 2025: $181K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $306K · Travel and Lodging: $38K · Consulting Fee: $26K · Food and Beverage: $8,370 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $306,241.75 |
| Travel and Lodging | $38,259.16 |
| Consulting Fee | $26,237.50 |
| Food and Beverage | $8,370.08 |
| Education | $117.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $172,410.53 | 2020-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $140,411.25 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Merck Sharp & Dohme LLC | $67,755.24 | 2023-2025 | Winrevair, Zerbaxa |
| Chiesi USA, INC. | $4,092.63 | 2025 | |
| Glaxosmithkline, LLC. | $946.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boston Scientific Corporation | $174.14 | 2023 | Ekosonic |
| Genzyme Corporation | $115.11 | 2021 | |
| Abbott Laboratories | $97.09 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $80.26 | 2022-2024 | Tezspire, Breztri |
| Amgen INC. | $47.42 | 2024-2025 | Tezspire |
| Baxter Healthcare | $42.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.23 | 2023 | |
| Integra Lifesciences Corporation | $30.98 | 2021 | |
| Liquidia Technologies, INC. | $26.71 | 2025 | Yutrepia |
| Mallinckrodt Hospital Products INC. | $23.54 | 2023 | Acthar |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.53 | 2021 | |
| Janssen Biotech, INC. | $20.05 | 2025 | Tremfya |
| Sandoz INC. | $17.34 | 2024 | Treprostinil |
| Verona Pharma, INC. | $16.62 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $13.82 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.